NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital
One in three patients achieved NEDA-3 3 years after starting cladribine, with the best outcomes observed in treatment-naïve patients, while its favorable safety profile and convenient dosing support long-term adherence and disease stability.
Authors
- Nora Berg Bjørnevoll
- Karl Bjørnar Alstadhaug
Institutions
- Nordland Hospital (NO)
- UiT The Arctic University of Norway (NO)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fneur.2025.1698334
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00